JP2523171C - - Google Patents
Info
- Publication number
- JP2523171C JP2523171C JP2523171C JP 2523171 C JP2523171 C JP 2523171C JP 2523171 C JP2523171 C JP 2523171C
- Authority
- JP
- Japan
- Prior art keywords
- protein
- solution
- reaction
- skim milk
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000006243 chemical reaction Methods 0.000 claims description 82
- 235000020183 skimmed milk Nutrition 0.000 claims description 72
- 102000004965 antibodies Human genes 0.000 claims description 38
- 108090001123 antibodies Proteins 0.000 claims description 38
- 238000003018 immunoassay Methods 0.000 claims description 35
- 238000005259 measurement Methods 0.000 claims description 24
- 229940099815 human protein S Drugs 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 13
- 102000038129 antigens Human genes 0.000 claims description 13
- 108091007172 antigens Proteins 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 229960000856 Protein C Drugs 0.000 claims description 7
- 102000017975 Protein C Human genes 0.000 claims description 7
- 108060005018 mobB Proteins 0.000 claims description 7
- 239000002806 plasmin inhibitor Substances 0.000 claims description 7
- 102400000680 Chondrocalcin Human genes 0.000 claims description 6
- 101800000938 Chondrocalcin Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 210000002826 Placenta Anatomy 0.000 claims description 5
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims description 3
- 108010088842 Fibrinolysin Proteins 0.000 claims description 3
- 102000005720 Glutathione Transferase family Human genes 0.000 claims description 3
- 108010070675 Glutathione Transferase family Proteins 0.000 claims description 3
- 229940012957 Plasmin Drugs 0.000 claims description 3
- 230000000896 plasminic Effects 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- 229960003180 Glutathione Drugs 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 230000001605 fetal Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 79
- 235000018102 proteins Nutrition 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108010045030 monoclonal antibodies Proteins 0.000 description 27
- 102000005614 monoclonal antibodies Human genes 0.000 description 27
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 19
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 229940096437 Protein S Drugs 0.000 description 16
- 102000029610 Protein S Human genes 0.000 description 15
- 108010066124 Protein S Proteins 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 14
- 206010029719 Nonspecific reaction Diseases 0.000 description 14
- 238000004164 analytical calibration Methods 0.000 description 14
- 238000011088 calibration curve Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000036647 reaction Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 11
- 229960000060 monoclonal antibodies Drugs 0.000 description 11
- 210000004080 Milk Anatomy 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 102000003839 Human Proteins Human genes 0.000 description 7
- 108090000144 Human Proteins Proteins 0.000 description 7
- 108090000284 Pepsin A Proteins 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 7
- 229940111202 pepsin Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 108091008117 polyclonal antibodies Proteins 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 102000012404 Orosomucoid Human genes 0.000 description 5
- 108010061952 Orosomucoid Proteins 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 230000036046 immunoreaction Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 102000006410 Apoproteins Human genes 0.000 description 4
- 108010083590 Apoproteins Proteins 0.000 description 4
- 230000035693 Fab Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000000903 blocking Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 229940072417 Peroxidase Drugs 0.000 description 3
- 108090000437 Peroxidases Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- -1 succinimide ester Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OBWSOTREAMFOCQ-UHFFFAOYSA-N 4-(4-amino-3,5-dimethylphenyl)-2,6-dimethylaniline;hydrochloride Chemical compound Cl.CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 OBWSOTREAMFOCQ-UHFFFAOYSA-N 0.000 description 2
- 102100007826 C4BPA Human genes 0.000 description 2
- 101700051748 C4BPA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 230000003169 placental Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1H-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-Tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZJGBFJBMTKEFNQ-UHFFFAOYSA-N 3-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 ZJGBFJBMTKEFNQ-UHFFFAOYSA-N 0.000 description 1
- BPOHHIFTIFSTNA-UHFFFAOYSA-N 4-(4-aminophenyl)-3-methylaniline;hydrochloride Chemical compound Cl.CC1=CC(N)=CC=C1C1=CC=C(N)C=C1 BPOHHIFTIFSTNA-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N ABTS Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Ammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101710010743 CSN1S1 Proteins 0.000 description 1
- 108060001965 CSN2 Proteins 0.000 description 1
- 102100014432 CSN2 Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 108009000338 Human Complement System Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100002378 RTTN Human genes 0.000 description 1
- 101700029166 RTTN Proteins 0.000 description 1
- 101710024753 SERPINB14 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 101500017928 human Saposin-D Proteins 0.000 description 1
- 229940100689 human protein C Drugs 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000003100 immobilizing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190018020A1 (en) | Methods for Early Diagnosis of Kidney Disease | |
| US10830771B2 (en) | PIVKA-II assay method and method for manufacturing reagent or kit for PIVKA-II immunoassay | |
| EP2068148B1 (en) | Method of measuring anticoagulation and reagent for measuring anticoagulation | |
| US9206250B2 (en) | Monoclonal antibodies and method of immunological analysis of D-dimer | |
| JP4413179B2 (ja) | 免疫学的粒子凝集反応方法 | |
| DK158246B (da) | Sandwichfremgangsmaade til bestemmelse af carcinoembryonalt antigen og oploesning til brug ved denne fremgangsmaade | |
| JP2867325B2 (ja) | 抗ｐｉｖｋａ−ｉｉ抗体産生ハイブリドーマ及び免疫学的測定方法 | |
| US10634676B2 (en) | Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody | |
| JPH1090268A (ja) | 免疫学的粒子凝集反応方法 | |
| EP0328679B1 (en) | Immunoassaying method and reagent kit for it | |
| JP2001504939A (ja) | プロテインｓの測定のための方法および試薬 | |
| US5366861A (en) | Immunoassay and reagent kit used therefor | |
| WO1992012429A1 (fr) | Analyse a sensibilite elevee de facteur tissulaire et kit utilise a cet effet | |
| EP0401370A1 (en) | Enzyme immunoassay according to sandwich method of human iv-type collagen | |
| JP2523171B2 (ja) | 免疫測定方法及びそれに用いる試薬キット | |
| JP2523171C (es) | ||
| EP0918218A2 (en) | Method for immunological assay | |
| EP0315447A2 (en) | Method of immunological measurement of human protein S and reagent and kit therefor | |
| JP4896022B2 (ja) | チトクロムｃの免疫化学的測定方法及び測定キット | |
| JP3142786B2 (ja) | 動脈硬化症の測定用キット及びこれに用いる抗体 | |
| JP2507317B2 (ja) | プラスミン―α２プラスミンインヒビタ―複合体の測定方法 | |
| JP3292937B2 (ja) | 残留農薬分析法 | |
| JPH10160735A (ja) | サンドイッチ測定法 | |
| JP2000184885A (ja) | 酸化ＬＤＬ−α▲１▼ＡＴ複合体を特異的に認識する抗体 | |
| JP4517353B2 (ja) | ＩｇＡ結合性アルカリ性ホスファターゼ６の測定方法およびそれに用いるキット |